Aadi Bioscience Transforms with In-Licensing of Novel ADC Portfolio, $100 Million Sale of FYARRO® and $100 Million PIPE Financing

Stock Information for null

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About null

Aadi Bioscience to Report Fourth Quarter and Full-Year 2024 Results and Corporate Update
Aadi Bioscience Announces Closing of $100 Million PIPE Financing
Aadi Bioscience Announces Approval of All Proposals at Special Meeting of Stockholders
Aadi Bioscience to Present at the TD Cowen 45th Annual Healthcare Conference
Aadi Bioscience Appoints David Dornan, PhD, as Chief Scientific Officer
Aadi Bioscience Filed Definitive Proxy Statement and Schedules Special Meeting of Stockholders for February 28, 2025
Aadi Bioscience Announces Financial Results for the Third Quarter 2024 and Provides Corporate Update
Aadi Bioscience to Report Third Quarter 2024 Results and Corporate Update

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.